Simple tumor enucleation may not decrease oncologic outcomes for T1 renal cell carcinoma: a systematic review and meta-analysis

Urologic Oncology: Seminars and Original Investigations Aug 24, 2017

Cao DH et al. – A systematic review and meta–analysis was performed to evaluate the clinical efficacy and safety of simple tumor enucleation (TE) for clinical T1 renal cell carcinoma. The authors concluded that TE is an effective and safe treatment for T1 renal tumors compared to traditional Partial Nephrectomy (PN) and has acceptable early oncology outcomes. However, these findings have to be validated through well designed studies.

Methods

  • The aim was to identify all trials that compared TE and traditional PN in patients with clinical T1 renal cell carcinoma through a systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases.

Results

  • A total of 3,218 patients were identified through 7 studies in this meta–analysis.
  • The TE group had significantly shorter operation times (mean difference [MD] = -21.93), shorter warm ischemia times (MD = -1.96), less blood loss (MD = -36.63), and lower surgical complication rates (odds ratio [OR] = 0.66) compared with the PN group.
  • No significant difference was found between the 2 groups in hospital stay duration, changes in estimated glomerular filtration rate, positive surgical margin rates, and local recurrence rates.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay